PRMT1‐Mediated SWI/SNF Complex Recruitment via SMARCC1 Drives IGF2BP2 Transcription to Enhance Carboplatin Resistance in Head and Neck Squamous Cell Carcinoma
Advanced Science · 2025-06 · 12 (22)
DOI: 10.1002/advs.202417460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.04.2025. Verfasst von Shixian Liu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Squamous Cell Carcinoma of Head and Neck, Drug Resistance, Neoplasm, Carboplatin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Anhui Provincial Natural Science Foundation, First Affiliated Hospital of Anhui Medical University.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) is a malignancy with poor prognosis and chemotherapy resistance. Here, protein arginine methyltransferase 1 (PRMT1) is identified as a key driver of carboplatin (CBP) resistance in HNSCC. Analyses of clinical samples, cell lines, patient‐derived organoids, and xenograft models reveal that PRMT1 promotes tumor growth and CBP resistance through a novel, methyltransferase‐independent mechanism. Conditional PRMT1 knockout suppresses tumorigenesis and enhances CBP sensitivity in vivo, highlighting its essential role in HNSCC progression. Mechanistically, PRMT1 recruits the SWI/SNF chromatin remodeling complex via direct interaction with SMARCC1, leading to the transcriptional activation of insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), which enhances CBP resistance and tumor growth. Notably, this function is independent of PRMT1's enzymatic activity, distinguishing it from its well‐established roles in arginine methylation. Furthermore, pre‐B‐cell leukemia homeobox 2 (PBX2) is identified as an upstream transcriptional activator that binds the PRMT1 promoter, driving its overexpression and reinforcing this oncogenic network. Clinically, high PBX2, PRMT1, SMARCC1, and IGF2BP2 expression correlates with malignant progression and poor prognosis in HNSCC patients. This study uncovers a previously unrecognized non‐catalytic function of PRMT1 and highlights the PBX2‐PRMT1‐SWI/SNF‐IGF2BP2 axis as a potential therapeutic target for overcoming CBP resistance in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Department of Otolaryngology, Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
- Department of Biochemistry & Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China.
- Department of Otolaryngology, Head and Neck Surgery, and Scientific Research and Experiment Center, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, 236800, China.
- Institutes of Biomedical Sciences, Children's Hospital of Fudan University, National Children's Medical Center, Fudan University, Shanghai, 200032, China.
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
ORCID-Profile: Xiaojun Zha
Förderung
- Innovative Research Group Project of the National Natural Science Foundation of China
- Anhui Provincial Natural Science Foundation
- First Affiliated Hospital of Anhui Medical University
- Affiliated Bozhou Hospital of Anhui Medical University Talent Introduction Scientific Research Start-up Foundation
- key research and development plan of Bozhou
- Anhui Medical University
- University Natural Science Research Project of Anhui Province
- Natural Science Foundation of Anhui Province
Zitieren
APA
Liu, S., Zhang, W., Liu, W., Ding, Z., Zhang, R., Han, Y., Niu, Z., Zhang, M., Li, H., Li, D., Wang, Z., Peng, J., Wu, Y., Han, Y., Xie, Z., Wu, J., Qin, L., Hu, Z., Chen, X., …, & Zha, X. (2025). PRMT1‐Mediated SWI/SNF Complex Recruitment via SMARCC1 Drives IGF2BP2 Transcription to Enhance Carboplatin Resistance in Head and Neck Squamous Cell Carcinoma. Advanced Science, 12(22). https://doi.org/10.1002/advs.202417460
Vancouver
Liu S, Zhang W, Liu W, Ding Z, Zhang R, Han Y, et al. PRMT1‐Mediated SWI/SNF Complex Recruitment via SMARCC1 Drives IGF2BP2 Transcription to Enhance Carboplatin Resistance in Head and Neck Squamous Cell Carcinoma. Advanced Science. 2025;12(22). doi:10.1002/advs.202417460
BibTeX
@article{Liu2025,
author = {Liu, Shixian and Zhang, Wentao and Liu, Weiwei and Ding, Zhao and Zhang, Ruijing and Han, Yuefeng and Niu, Zihao and Zhang, Mengdie and Li, Hui and Li, Dapeng and Wang, Zixi and Peng, Jie and Wu, Yu and Han, Yanxun and Xie, Zihui and Wu, Jing and Qin, Liang and Hu, Zhongdong and Chen, Xu and Hu, Yunlong and Liu, Yehai and Ma, Shiyin and Zha, Xiaojun},
title = {PRMT1‐Mediated SWI/SNF Complex Recruitment via SMARCC1 Drives IGF2BP2 Transcription to Enhance Carboplatin Resistance in Head and Neck Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {22},
doi = {10.1002/advs.202417460}
}
EUVIMED